Elsevier

Gait & Posture

Volume 36, Issue 3, July 2012, Pages 471-476
Gait & Posture

Full length Article
Postural sway as a marker of progression in Parkinson's disease: A pilot longitudinal study

https://doi.org/10.1016/j.gaitpost.2012.04.010Get rights and content

Abstract

Objective measures of postural control that are sensitive to Parkinson's disease (PD) progression would improve patient care and accelerate clinical trials. Although measures of postural sway during quiet stance in untreated PD have been shown to differ from age-matched control subjects, it is not known if sway measures change with disease progression in early PD. In this pilot study, we asked whether accelerometer-based metrics of sway could provide a practical tool for monitoring progression of postural dyscontrol in people with untreated or newly treated PD.

We examined 13 subjects with PD and 12 healthy, age-matched control subjects. The PD subjects had been recently diagnosed and had not started any antiparkinsonian medications at the baseline session. All subjects were tested 3–6 months and 12 months after the baseline session. Subjects were asked to stand quietly for two minutes while wearing an inertial sensor on their posterior trunk that measured trunk linear acceleration.

Our results suggested that objective sway measures deteriorated over one year despite minimal changes in UPDRS motor scores. Medio-lateral (ML) sway measures were more sensitive than antero-posterior sway measures in detecting progression. The ML JERK was larger in the PD group than the control group across all three testing sessions. The ML sway dispersion and ML sway velocity were also significantly higher in PD compared to control subjects by the 12-month evaluation. It is feasible to measure progression of PD prior to onset of treatment using accelerometer-based measures of quiet standing.

Highlights

► Objective sway measures deteriorated over one year. ► UPDRS motor scores did not show significant changes over one year. ► Medio-lateral (ML) sway measures were more sensitive than antero-posterior sway measures in detecting progression.

Introduction

The defining motor features of Parkinson's disease (PD) are characterized by their insidious onset and inexorable, but variable progression. Reliable and validated, objective markers that can monitor PD progression throughout its course would dramatically improve patient care and accelerate clinical trials [1]. Clinical trials of neuroprotective interventions, in particular, require measures that are able to track PD progression, even in the early stage of the disease and before patients start taking antiparkinsonian medications.

Measures of postural control have not been considered viable candidates for measurement of progression in early-to-moderate, untreated PD because postural problems are not clinically apparent at this stage [2], [3]. In fact, an abnormal response to the Pull test marks the progression from Stage II to Stage III of the Hoehn and Yahr scale and the PIGD (postural instability and gait disorder) subscore of the UPDRS is nearly normal in Stages I and II [3]. Postural problems in patients with PD in clinical trials are usually measured with the PIGD, that includes: sit-to-stand, posture, pull test, and gait evaluated on a 0–4 scale [4], [5]. Although the PIGD is easy to use, does not require equipment, and is quick to administer, the results obtained are subjective and are not sensitive enough to detect early disease progression. Moreover, a recent study that evaluated the responsiveness of different PD scales to change over time showed only a small to moderate effect size of the UPDRS Motor part III [6].

Contrary to the general assumption that postural problems develop later in PD, several recent studies, utilizing force-plate measurements, have shown that postural sway is abnormal early in the disease, even in PD patients with mild symptoms (e.g. Motor UPDRS < 21) [7], [8]. Quantitative measures of postural sway reflect how the nervous system controls the complex sensorimotor task of maintaining bipedal equilibrium [9]. The basal ganglia play an important role in control of axial tone, postural response amplitude, and interpretation of somatosensory information [10], [11], [12]. Thus, postural abnormalities in early PD are not surprising. Although abnormalities in postural sway have been shown to predict past and future falls [13], [14], it is not possible for clinicians to rate measures of postural sway (e.g. sway amplitude, velocity, frequency, or jerkiness), because these are subtle abnormalities that are not always evident or quantifiable by clinical observation.

Our recent studies have shown that neural control of postural sway is compromised in subjects with untreated PD [15] and levodopa administration increases several postural sway parameters [16]. We recently demonstrated that accelerometer-based measures of postural sway can distinguish subjects with untreated PD from age-matched control subjects. Sway jerkiness was shown to be one of the most discriminative measures in differentiating untreated PD from age-matched control subjects. JERK is an indicator of sway smoothness; a higher value indicates more jerky or less smooth sway (i.e. more postural sway corrections). It reflects corrections made by the nervous system to control sway while maintaining a quiet, upright posture.

In the current pilot study, we investigated whether this type of accelerometer-based analysis of spontaneous sway could provide a feasible tool for monitoring progression of postural dyscontrol in people with untreated or newly treated PD. Monitoring progression of postural control with accelerometer-based measures may represent a practical, inexpensive alternative to force plate measures of postural sway because of its unobtrusiveness and portability, key factors for use in clinical or community setting.

Section snippets

Subjects

We followed 13 subjects with idiopathic PD (7 male and 6 female, 60.4 ± 8.5 years) and 12 healthy, age-matched control subjects (5 male and 7 female, 60.2 ± 8.2 years) for 12 months. Control subjects were free of any neurological or musculoskeletal impairment that could affect postural control and were either spouses or friends of subjects with PD. A movement disorders neurologist diagnosed our PD subjects. The PD subjects were free of musculoskeletal disorders and, as inclusion criteria, were not

Changes in sway measures over one year

  • Trunk accelerations from a representative control subject and an untreated PD subject are shown at baseline, 3–6 m and 12 m in Fig. 1. While traces of the control subject did not change across time, there was a progressive increase in the AP and ML acceleration excursions for the PD subject (P13).

  • ML sway measures detected more differences between control and PD subjects than the AP sway measures (see Table 2). The ML JERK was significantly larger in the PD group compared to the control group at

Discussion

Results of this pilot longitudinal study suggest that quantitative postural sway measures are able to identify postural dyscontrol early in PD progression and thus may be useful to study progression of Parkinson's disease in early stages of the disease. However, trends toward a slowing in progression of postural sway dyscontrol with initiation of levodopa suggests that more studies are needed to determine if initiation of medication in early PD masks progression of disease.

In this pilot study,

Conflict of interest statement

This research was supported by grants from the Kinetics Foundation and the National Institute on Aging (NIA, 006457). This research was also supported in part by the Intramural Research Program of the NIH. Dr. Horak was a consultant for Kinetics Foundation. This potential conflict of interest has been reviewed and managed by OHSU.

Acknowledgements

We thank all the participants, Triana Nagel for recruiting subjects and data collection assistance, and Edward King for technical assistance. This research was supported by grants from the Kinetics Foundation and the National Institute on Aging (NIA, 006457). This research was also supported in part by the Intramural Research Program of the NIH. Dr. Horak was a consultant for Kinetics Foundation.

References (25)

  • M.M. Hoehn et al.

    Parkinsonism: onset, progression and mortality

    Neurology

    (1967)
  • S. Fahn et al.

    The UPDRS Development Committee. Unified Parkinson's disease rating scale

  • Cited by (0)

    View full text